Hyperion Therapeutics (NASDAQ: HPTX) shares are surging today following news that its drug RAVICTI was approved by the Food and Drug Administration for the treatment of a rare disease called urea cycle disorder. While RAVICTI isn't the first drug to treat the disease, its convenience is head and shoulders above the existing option. Follow along in the video below as health care bureau chief Brenton Flynn discusses the news and what's next for Hyperion now that RAVICTI is approved.